How Israel Gave One Million Covid-19 Vaccine Doses So Fast

Facebook ↗WhatsApp ↗

Originally published 2021-01-02.

On 1 January 2021, less than two weeks after its campaign began, Israel passed one million Covid-19 vaccinations. According to Our World in Data figures reported by The Times of Israel that day, about 11.5% of the population had received a dose, while second-placed Bahrain stood at roughly 3.5% and the UK at about 1.4%. No other country was close.

Israel Gives a Covid-19 Vaccine Dose to One Million People

Below we look at how Israel moved so quickly, what the numbers did and did not mean, the debates that came with the rollout, and what happened in the months that followed.

The one-million milestone at a glance

Israel's national vaccination drive, branded "Give a Shoulder," started on 19 December 2020, with Prime Minister Benjamin Netanyahu receiving the first shot on live television. By New Year's Day the count had passed seven figures. Health Ministry data released that day showed that about 41% of Israelis over 60 had already had a first dose, alongside large numbers of health workers and medically vulnerable people.

Health Minister Yuli Edelstein marked the moment with a simple update: "Yesterday we broke a new record and vaccinated 153,430 people. Today we'll pass one million." The government's stated target was about 2.25 million people, out of a population of roughly 9.3 million, by the end of January.

The country was also in a difficult phase of the pandemic. It had entered its third nationwide lockdown that week, daily infections had topped 5,000, and since the start of the outbreak it had recorded more than 426,000 cases and at least 3,338 deaths.

Why Israel could move so fast

Several features of Israel's situation made a rapid rollout possible:

  • Early, large supply. Israel secured a big quantity of the Pfizer-BioNTech vaccine relative to its population. In exchange, it agreed to share anonymised data on how the vaccine performed across the population, effectively making the country a real-world study.
  • A digital health system. Every resident must belong to one of four health maintenance organisations (HMOs). These insurers hold detailed electronic records, so they could identify older and high-risk members and contact them directly by phone, text or email.
  • A small, centralised country. Short distances and a dense network of clinics made it easier to set up vaccination centres and keep the ultra-cold Pfizer doses moving.
  • Political urgency. The campaign coincided with a run-up to elections in March 2021, and the government made speed a national priority.

Netanyahu visited a vaccination centre in Umm al-Fahm, an Arab city in northern Israel, on the day of the milestone, saying it was important that Arab citizens get vaccinated quickly because "it's saving lives." Arab citizens make up about a fifth of Israel's population and had been slower to come forward, partly because of long-standing distrust of state institutions. Many observers also read the visit, his first to such towns in years, as an attempt to win votes before the election.

What the numbers meant, and what they did not

The headline figure counted first doses. The Pfizer-BioNTech vaccine was given as two shots about three weeks apart, so one million first doses did not mean one million people fully protected. Comparisons between countries also depended on matching dates and definitions; the UK figure quoted at the time, for example, was several days old.

It is also worth correcting a popular misunderstanding of "95% efficacy." In the vaccine's large phase 3 trial, the vaccinated group had about 95% fewer cases of symptomatic Covid-19 than the placebo group. That does not mean 19 out of every 20 vaccinated people who meet the virus will stay healthy; it is a relative reduction in illness compared with no vaccine, measured under trial conditions.

The comparison with flu shots is similarly rough. The US Centers for Disease Control and Prevention (CDC) publishes seasonal flu vaccine effectiveness estimates that have ranged from about 19% to 60% since 2009, depending on the year and how well the vaccine matched circulating strains. Covid-19 vaccines did perform very strongly against symptomatic illness at first, but the two figures come from different kinds of studies and are not directly interchangeable.

Supply worries and the Moderna question

Speed brought a practical problem: Israel risked running through its first Pfizer deliveries before the next ones arrived. Officials warned that a shortage could force a pause of about two weeks in January, during which only second doses would be given.

Israeli Channel 12 reported that one million Moderna doses, originally expected in March, would arrive the following week. The Health Ministry said it had no such information, while Moderna sources were quoted as saying the shipment was ready pending final approval. At the time, the early arrival was therefore a report rather than a confirmed plan.

The UK's different bet on second doses

Britain, then facing one of the worst outbreaks in the world, chose a different route. On advice from its Joint Committee on Vaccination and Immunisation, the government decided to give second doses up to 12 weeks after the first instead of three, so that more people in at-risk groups could get some protection sooner.

Pfizer and BioNTech pushed back in a joint statement, warning that their vaccine had not been tested on other schedules and adding: "There is no data to demonstrate that protection after the first dose is sustained after 21 days." The European Medicines Agency said the interval should stay within 42 days. The UK also prepared to roll out the Oxford-AstraZeneca vaccine, which can be stored in an ordinary fridge, unlike the Pfizer shot, which had to be shipped at around minus 70 degrees Celsius.

In January 2021 the choice was a calculated gamble made under emergency conditions, and the right gap between doses remained a lively scientific debate for months afterwards.

What happened next

Israel kept up its pace. Roughly a fifth of the population had a first dose within three weeks, and by late February 2021 at least 4.8 million people had received one. A "Green Pass" system, introduced on 21 February 2021, let vaccinated or recovered people enter gyms, hotels and other venues. By March, Israel had the highest per-capita vaccination rate in the world, and a study published in The Lancet later estimated that the campaign prevented roughly 5,500 deaths between December 2020 and April 2021.

The campaign also drew criticism. Uptake remained lower among Haredi Jewish and Arab citizens for months. Palestinians in the West Bank and Gaza were not covered by the Israeli programme, since their health care falls under the Palestinian Authority in line with the Oslo Accords, a position that drew international debate. Israel later vaccinated more than 100,000 Palestinian workers who entered Israel, and a 2021 plan to transfer about one million soon-to-expire doses to the Palestinian Authority collapsed when the authority said they would expire too soon to use.

In late July 2021 Israel became one of the first countries to offer a third booster dose, starting with people over 60. By then the one-million milestone looked like an early chapter in a much longer story, one that turned Israel into a closely watched test case for how mass vaccination works in the real world.

Sources: The Times of Israel: Israel reaches 1 million mark in vaccinations (1 January 2021); Wikipedia: COVID-19 vaccination in Israel; Wikipedia: Pfizer-BioNTech COVID-19 vaccine; The Scotsman: Covid vaccine manufacturers say second doses should not be delayed (January 2021); CDC: Flu vaccine effectiveness studies.

COMMENTS